Register
EMA recommends LFT for women on ulipristal for uterine fibroids |
Journal Updates
eMediNexus Coverage from: 
EMA recommends LFT for women on ulipristal for uterine fibroids
eMediNexus,  11 February 2018
remove_red_eye 990 Views
#Obstetrics and Gynecology #Urology

0 Read Comments                

The European Medicines Agencys (EMAs) Pharmacovigilance Risk Assessment Committee (PRAC) recommended liver function testing at least monthly for women taking ulipristal acetate (Esmya, Gedeon Richter) for uterine fibroids due to reports of serious liver damage, requiring liver transplantation in some cases.

To comment on this article,
create a free account.
Sign Up to instantly read 30000+ free Articles & 1000+ Case Studies
Create Account

Already registered?

Login Now